R&D Trends

MorphoSys, Celgene to jointly develop cancer program

Tuesday, July 2, 2013 01:15 PM

Global biopharma companies MorphoSys and Celgene have agreed to jointly develop MOR202 globally and co-promote it in Europe. MOR202 is a fully human monoclonal antibody targeting CD38 to treat patients with multiple myeloma and certain leukemias. It currently is being evaluated in a phase I/IIa trial in patients with relapsed/refractory myeloma. The companies will collaborate on the development of MOR202 in multiple myeloma and other indications and share costs.

More... »

Sarah Cannon, AstraZeneca partner for oncology

Tuesday, July 2, 2013 12:53 PM

Sarah Cannon Research Institute (SCRI) and AstraZeneca will collaborate to develop new AstraZeneca oncology compounds. The companies will work on molecular profiling to classify tissue based on genetic profiles for the purpose of treating cancers and predicting response to therapy.

More... »

Cytokinetics, Astellas collaborate on skeletal muscle activation

Thursday, June 27, 2013 03:15 PM

Biopharmaceuticals Cytokinetics and Astellas Pharma are collaborating on the research, development and commercialization of skeletal muscle activators. The primary objective of the collaboration is to advance novel therapies for diseases and medical conditions associated with muscle weakness. The companies will jointly conduct research in the area of skeletal muscle activation.

More... »

TSRI awarded $1.4M for chronic leukemia research

Thursday, June 27, 2013 01:09 PM

Scientists from The Scripps Research Institute (TSRI) have been awarded more than $1.4 million from the National Cancer Institute of NIH to create a potential new drug to attack the malignant cells that cause chronic lymphocytic leukemia (CLL).

More... »

Numecent, TAI Software partner

Thursday, June 27, 2013 12:00 PM

Numecent, the cloudpaging innovator, has entered into a partnership with TAI Software to deploy cloudpaging for HIPAA compliant HealthCare and Human Services solutions.

More... »

Seattle Genetics, Bayer in ADC collaboration

Wednesday, June 26, 2013 03:13 PM

Biotech Seattle Genetics has entered into an antibody-drug conjugate (ADC) collaboration with Bayer HealthCare. Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets. Seattle Genetics also is eligible to receive up to $500 million in potential milestone payments, as well as royalties on worldwide net sales of any resulting products under the multi-target collaboration. Bayer is responsible for research, product development, manufacturing and commercialization of all products. 

More... »

Karolinska Development, Novo Seeds and Finnvera invest in Forendo Pharma

Wednesday, June 26, 2013 02:53 PM

Karolinska Development has invested in Forendo Pharma, a new drug development company based in Finland, together with Novo Seeds and Finnvera.

More... »

AmVac receives two E.U. grants for development of novel vaccines

Tuesday, June 25, 2013 09:37 AM

Biopharmaceutical AmVac has announced that the E.U. approved two grant applications under the seventh framework program (FP7) for the development of vaccines against flu and leishmaniasis. The projects are joint initiatives of AmVac, other European companies and research institutes with expertise in vaccine design and development. Total funding for all participating partners is approximately $7.8 million and $7.2 million, respectively, over five years. Within the funding periods, both vaccines are expected to complete phase I clinical trials.

More... »

Global Awareness Day unites ALS/MND Associations

Monday, June 24, 2013 03:36 PM

The nonprofit ALS Association has joined forces with the International Alliance of ALS/MND Associations for ALS/MND Global Awareness Day. Outside the U.S., amyotrophic lateral sclerosis (ALS) is more commonly known as motor neuron disease or MND.

More... »

$100,000 grant aids rapid cancer detection program

Monday, June 24, 2013 03:27 PM

A rapid cancer detection program developed through collaboration between local physicians, the Scottsdale Healthcare Research Institute and Virginia G. Piper Cancer Center at Scottsdale Healthcare has been awarded a $100,000 grant from the Industrial Development Authority (IDA)of Scottsdale.

More... »